ArticleJournal of translational medicine2025
Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial-mesenchymal transition in chronic hepatic injury.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEndothelial-to-mesenchymal transition (EndMT) has emerged as a pivotal pathological process during liver fibrosis. Angiotensin II receptor type 1 (AT1R) has been implicated in the regulation of EndMT and is considered a promising target for therapeutic intervention. Consequently, the identification of specific AT1R inhibitors may offer a novel approach to alleviate the liver fibrosis. PURPOSE: This study aims to evaluate the potential of Betulinic Acid (BA) as a natural AT1R inhibitor and investigate its underlying mechanisms in the context of EndMT and liver fibrosis treatment.
methodThe binding interaction between BA and AT1R was evaluated using AlphaFold 3 (AF3) predictions, molecular dynamics (MD) simulations, and in vivo validation through At1r gene knockout in animals. A mouse model of liver fibrosis, induced by a Western diet combined with CCl
resultAF3 and MD simulations revealed stable binding between BA and AT1R, which was further confirmed in the At1r knockout mouse model. Pharmacodynamic studies indicated that long-term oral administration of BA did not induce significant pathological alterations in liver and kidney functions, blood routine, or major organs in mice. However, notable improvements in liver fibrosis-related pathological indicators were observed. Further pharmacological analysis demonstrated that BA treatment substantially inhibited EndMT in the context of liver fibrosis, with the PI3K-AKT signaling pathway in endothelial cells identified as a potential mechanism.
conclusionThis study presents the first evidence that BA alleviates liver fibrosis by acting as an AT1R antagonist to inhibit EndMT. These findings underscore the potential therapeutic application of BA as an AT1R inhibitor in the management of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.